Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
COA on request
- Arrives Thu, Oct 22 – Tue, Oct 27Free standard shipping on orders over $100
- Free shipment protectionLost, stolen, or damaged? We replace it, on us.
- Overnight and 2-day optionsPick your speed at checkout
GLP-2 (TR)
Metabolic Research Peptide
A 39-residue peptide that activates both the GIP and GLP-1 receptors, carrying a fatty-acid side chain that extends its half-life. It is studied in metabolic research comparing dual-incretin signaling with single-receptor agonists. For in vitro laboratory research use only.
- Arrives Thu, Oct 22 – Tue, Oct 27Free standard shipping on orders over $100
- Free shipment protectionLost, stolen, or damaged? We replace it, on us.
- Overnight and 2-day optionsPick your speed at checkout
Compound Information
What is GLP-2 (TR)?
- CAS number
- 2023788-19-2
- Molecular weight
- 4,813.53 g/mol
- Amino acids
- 39
- Formula
- C225H348N48O68
- Sequence
- 39-residue GIP-based analog; Aib at 2 and 13; C20 diacid on Lys20 via gamma-Glu + 2x AEEA; C-terminal amide
Stability information
- Protect from light
- Avoid repeated freeze-thaw cycles
Conditions apply to sealed research vials as supplied. Batch details are on the Certificate of Analysis above.
Sources & References
Peer-reviewed research
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
View Source ↗Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
View Source ↗GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
View Source ↗Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
View Source ↗Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
View Source ↗Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
View Source ↗Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
View Source ↗A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)
View Source ↗Frequently Researched Together
Related research compounds
Tesamorelin
GHRH analog
GLP-1 (SM)
Metabolic Research Peptide
Cagrilintide
Long-acting amylin analog
SNAP-8
Dermal Peptide
IGF-1 LR3
Long-acting IGF-1 analog
Glutathione
Antioxidant & Detoxification Peptide
BPC-157
Body-protective compound peptide
CJC-1295 / Ipamorelin (No DAC)
Secretagogue Peptide
GHK-Cu
Copper-binding tripeptide